The sodium/glucose cotransporter 2 (SGLT2) inhibitor empagliflozin and glucagon-like peptide-1 receptor (GLP1R) agonist semaglutide, medications originally developed to treat diabetes and/or obesity, have demonstrated clinically significant cardiovascular benefits (Cowie and Fisher, 2020; Sattar et al., 2021; Lincoff et al., 2023). Here, SLC5A2 is linked to obesity due to melanocortin 4 receptor deficiency.